XETR
SRT3
Market cap13bUSD
Jun 18, Last price
217.10EUR
1D
-4.86%
1Q
5.29%
Jan 2017
203.30%
Name
Sartorius AG
Chart & Performance
P/E
178.47
P/S
4.43
EPS
1.22
Div Yield, %
0.34%
Shrs. gr., 5y
0.17%
Rev. gr., 5y
13.10%
Revenues
3.38b
-0.44%
Net income
84m
-59.06%
CFO
976m
+14.36%
Dividend
Apr 02, 20240.74 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sartorius AG, a German company established in 1870 and based in Göttingen, is a global supplier of innovative bioprocess solutions and laboratory products and services. The company's extensive portfolio supports life science research, biopharmaceutical manufacturing, quality control, and other applied industries worldwide. Its offerings encompass a wide array of sophisticated tools and consumables, including: Advanced Analytics: Biosensors, label-free detection, and SPR systems; live-cell analysis platforms, flow cytometry, and related reagents. Cell Culture and Fermentation: Various bioreactors (e.g., single-use, stainless steel, benchtop) along with specialized media (for antibodies, recombinant proteins, stem cells, viral vaccines) and other essential reagents like buffers and microcarriers. Filtration and Separation: A comprehensive range of membranes, filter papers, syringe filters, and diverse filtration and ultrafiltration devices for sterile processing, sample preparation, and clarification. Laboratory Essentials: Weighing and pipetting systems, centrifuges, industrial microbiology systems, and water purification units. Process Solutions: Fluid management, process chromatography, and advanced analytical technologies coupled with data analytics. Beyond products, Sartorius provides crucial support services such as bioprocess development and engineering, protein expression system services, media and process optimization, testing, instrument services, and validation assistance.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||